Clinical trials: Ischemic Lesions
Coronary Artery Disease
TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions
TAXUS ATLAS is a global, multi-center, single-arm, non-inferiority trial comparing results from patients treated with the TAXUS Liberté stent to an historical TAXUS Express control.
- Trial name
- NCT00371709
- Testing
- TAXUS Liberté-SR, TAXUS™ Express
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 871 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
The Dual Antiplatelet Therapy Study (DAPT Study)
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety…
- Trial name
- NCT00977938
- Testing
- Clopidogrel & Aspirin, Prasugrel & Aspirin
- Where
- 256 sites in United States, Australia and 8 more
- Volunteers
- 25,682 people
- Sponsor
- Baim Institute for Clinical Research
Coronary Artery Disease
Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents for Long-Coronary Lesions
This randomized study is a multi-center, randomized, study to compare the efficacy of biolimus A9-eluting stent (Nobori) vs. everolimus-eluting stent (Promus Element) for long coronary lesions.
- Trial name
- LONG-DES-V (NCT01186120)
- Testing
- Biolimus A9-eluting stent, Everolimus-eluting stent
- Where
- 11 sites in South Korea
- Volunteers
- 500 people
- Sponsor
- Seung-Jung Park
Coronary Disease, Coronary Artery Disease
SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
Prospective, randomized, active-control, single blind, parallel two-arm multi-center clinical trial comparing XIENCE V® Everolimus Eluting Coronary Stent System to the approved commercially available active control TAXUS™…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- SPIRIT II (NCT00180310)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 32 sites in Austria, Belgium and 11 more
- Volunteers
- 300 people
- Sponsor
- Abbott Medical Devices
In-stent Restenosis, Ischemic Heart Disease
The PREVAIL Study
To evaluate the clinical safety and efficacy of a new Medtronic Coronary Drug-Coated Balloon Catheter in the treatment of de novo lesions, small vessel disease or In-Stent Restenosis with coronary lesions previously treated with…
- Conditions
- In-stent Restenosis, Ischemic Heart Disease, Coronary Artery Disease
- Trial name
- PREVAIL (NCT03260517)
- Testing
- Medtronic Coronary Drug-Coated Balloon Catheter
- Where
- 10 sites in Belgium, Italy and 1 more
- Volunteers
- 50 people
- Sponsor
- Medtronic Vascular
Carotid Artery Disease, Stroke Prevention
Diffusion Weighted-MRI Based Evaluation of the Effectiveness of Endovascular Clamping During Carotid Artery Stenting With the Mo.Ma Device.
The purpose of this study is to detect new ischemic lesions after carotid artery stenting (with the Cristallo Ideale stent), in patients with high grade carotid artery stenosis, by diffusion-weighted magnetic resonance imaging…
- Trial name
- DESERVE (NCT00798512)
- Testing
- Carotid artery stenting
- Where
- 6 sites in Germany, Italy and 1 more
- Volunteers
- 127 people
- Sponsor
- Invatec S.p.A.
Coronary Artery Disease (CAD), Stenosis Coronary
Brazilian Prospective Registry of the Inspiron EVO Drug-Eluting Stent in Complex Coronary Lesions
The objective is to evaluate the efficacy and safety of the Inspiron™ EVO drug-eluting stent in complex coronary lesions in a real-world population.
- Conditions
- Coronary Artery Disease (CAD), Stenosis Coronary, Small Vessel Ischemic Disease, Multivessel Coronary Artery Disease
- Trial name
- PCI EVOlution (NCT07491107)
- Testing
- Inspiron EVO Drug-Eluting Stent
- Where
- Brazil
- Volunteers
- 2,000 people
- Sponsor
- Scitech Produtos Medicos SA
Coronary Artery Disease
Optical Coherence Tomography for Drug Eluting Stent Safety
Increasing lesion complexity in percutaneous coronary interventions (PCI) has warranted the use of overlapping drug-eluting stents.
- Trial name
- ODESSA (NCT00693030)
- Testing
- sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson & Johnson Co), paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS), zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA)
- Where
- Italy
- Volunteers
- 77 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Coronary Artery Disease, Myocardial Ischemia
Comparison of Percutaneous Coronary Intervention Optimization With Fractional Flow Reserve Versus Intravascular Ultrasound in the Treatment of Long Coronary Artery Lesions
A single center, prospective, observational study to compare fractional flow reserve (FFR) and intravascular ultrasound (IVUS) percutaneous coronary intervention (PCI) optimization strategies on the functional PCI result…
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT05732324
- Testing
- IVUS guided PCI optimization, FFR guided PCI optimization, FFR measurement
- Volunteers
- 154 people
- Sponsor
- Vilnius University Hospital Santaros Klinikos
Lower Limb Ischemia
Endovascular Management of Combined Common Femoral and Superficial Femoral Arteries Lesions
The purpose of this study is to evaluate the technical feasibility, safety, and 1-year clinical efficacy of the endovascular treatment of patients with atherosclerotic common femoral artery (CFA) obstructions with associated…
- Trial name
- NCT05569369
- Testing
- angioplasty and stenting
- Volunteers
- 25 people
- Sponsor
- Sohag University
Grey-zone Fractional Flow Reserve, Intermediate Coronary Lesions
A Trial in Stable Intermediate Coronary Lesions and Grey-zone FFR Values
In this randomised controlled trial of patients with stable angina and documented intermediate coronary disease with indeterminate or "grey-zone" Fractional Flow Reserve (FFR) we will randomise patients to either optimal medical…
- Conditions
- Grey-zone Fractional Flow Reserve, Intermediate Coronary Lesions, Stable Angina, Coronary Physiology
- Trial name
- GzFFR (NCT02425969)
- Testing
- PCI, Optimal Medical Therapy
- Where
- United Kingdom
- Volunteers
- 108 people
- Sponsor
- Golden Jubilee National Hospital
Coronary Disease
Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution in Native Coronary Artery Lesions
The primary objective of this study is to evaluate the target lesion failure rate of the NEVO Sirolimus-eluting Coronary Stent System.
- Trial name
- NEVO RES-II (NCT00714883)
- Testing
- NEVO™ Sirolimus-eluting Coronary Stent System
- Where
- 2 sites in Germany, Latvia
- Volunteers
- 3 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
Diabetes Drug Eluting Sirolimus Stent Experience in Restenosis Trial
The main objective of this study is to assess the safety and effectiveness of the Sirolimus-eluting stent CYPHERTM and/or updated version in reducing angiographic in-stent late loss in de novo native coronary lesions of diabetic…
- Trial name
- DESSERT (NCT00497172)
- Testing
- CYPHER Sirolimus-eluting stent, Bx SONIC bare metal stent
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Cordis US Corp.
Heterozygous Familial Hypercholesterolemia (HeFH)
"Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)"
This multicenter, non-randomized interventional study aims to assess coronary artery disease progression over 5 years in patients with genetically confirmed heterozygous familial hypercholesterolemia (HeFH), using coronary…
- Trial name
- DESTINY-FH (NCT07427472)
- Testing
- Coronary computed tomography angiography
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coronary Artery Disease
SELUTION 4 De Novo Small Vessel IDE Trial
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as…
- Trial name
- NCT05946629
- Testing
- PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES
- Where
- 70 sites in United States, Belgium and 1 more
- Volunteers
- 960 people
- Sponsor
- M.A. Med Alliance S.A.
Atherosclerosis, Ischemia Limb
Efficacy and Safety Comparison of the Endovascular and the Hybrid Methods for the Treatment of Prolonged Atherosclerotic Lesions of the Femoral-popliteal Segment Above the Knee, TASC II, Type D
A recent study, where the authors studied the effectiveness of stenting of prolonged lesions (>200 mm) of the femoral-popliteal segment with nitinol stents (TASC II, D), showed unsatisfactory primary patency rates (45%) within 2…
- Conditions
- Atherosclerosis, Ischemia Limb, Superficial Femoral Artery Occlusion, Popliteal Artery Occlusion
- Trial name
- NCT04590131
- Testing
- recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal., recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Coronary Artery Disease
BIOTRONIKS - Safety and Performance in de NOvo Lesion of NatiVE Coronary Arteries With Magmaris- Registry: BIOSOLVE-IV
The registry will investigate the clinical performance and long-term safety of Magmaris in a real world setting
- Trial name
- BIOSOLVE-IV (NCT02817802)
- Testing
- Magmaris
- Where
- 2 sites in Belgium, Hong Kong
- Volunteers
- 2,066 people
- Sponsor
- Biotronik AG
Ischemic Heart Disease, Myocardial Ischemia
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
This is a prospective, multi-center, open label, randomized study to evaluate the efficacy and safety of The TIVOLI Biodegradable polymer Rapamycin-Eluting Stent comparing with The FIREBIRD2™ Rapamycin-eluting Stent (DES) for…
- Conditions
- Ischemic Heart Disease, Myocardial Ischemia, Coronary Artery Lesions,Primary, Coronary Disease
- Trial name
- NCT01681381
- Testing
- Tivoli® DES, Firebird2® DES
- Where
- China
- Volunteers
- 2,790 people
- Sponsor
- Essen Technology (Beijing) Co., Ltd.
Coronary Artery Disease
H-Side Branch Stent, A New Stent for the Treatment of True Bifurcation Lesions
Intervention for coronary bifurcation lesion is about 10~20% of entire percutaneous coronary intervention (PCI). Bifurcation lesion is difficult to be treated and prognosis of PCI at bifurcation lesion has been poorer compared to…
- Trial name
- NCT02037386
- Testing
- H-side branch stent
- Sponsor
- Yonsei University
Critical Limb Ischemia
MOTIV BTK Randomized Controlled Trial
Pre-market clinical evaluation of the MOTIV Sirolimus-Eluting Bioresorbable Scaffold for the planned treatment of infrapopliteal lesions.
- Trial name
- NCT05406622
- Testing
- MOTIV Sirolimus-Eluting Bioresorbable Scaffold, Percutaneous Transluminal Angioplasty (PTA) Device
- Where
- 26 sites in United States, Germany
- Volunteers
- 292 people
- Sponsor
- REVA Medical, Inc.